The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 67 results
Sort by date: Descending
Encores: Not included
Bipolar Disorder
Schizophrenia
USPC 2026 POSTER
Olanzapine and Samidorphan Combination For Early and Sustained Treatment of Schizophrenia and Bipolar I Disorder: A Plain Language Summary
AUTHOR(S)

Roger S. McIntyre, MD,1,2  Tarrah Holliday, ARNP, PMHNP-BC,3 Chelsie Monroe, MSN, APN, PMHNP-BC,4 Mark S. Todtenkopf, PhD,5 James A. McGrory, PhD,5 Craig Chepke, MD, DFAPA6,7

View poster
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
USPC 2026 POSTER
Long-Term Safety and Efficacy of Olanzapine/Samidorphan in a Subgroup of Early-in-Illness Patients
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Shifang Liu, PhD,2 Christoph U. Correll, MD3-7

View poster
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
USPC 2026 POSTER
Acute Care Events Following Initiation of Olanzapine/Samidorphan Among Patients With Schizophrenia or Bipolar I Disorder and Comorbid Alcohol Use Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Andrew Penn, MS, PMHNP-BC,2 Julie A. Carbray, PhD, PMHNP-BC, PMHCNS-BC, FAAN,3 Madhukar H. Trivedi, MD,4 Alejandro G. Hughes, MPH,5 Noah S. Webb, PhD,5 Kanika Ballani, PharmD, MBA,6 Michael J. Doane, PhD,6 Hemangi R. Panchmatia, MSc,6 Andrew J. Cutler, MD7,8

View poster
Bipolar Disorder
Schizophrenia
Sleep-wake disorders
USPC 2026 POSTER
Association Between Depression and Disease Burden in Narcolepsy and Idiopathic Hypersomnia: Patient-Centered Results From the ASPIRE Study
AUTHOR(S)

Craig Chepke,1,2 Michael J. Doane,3 Lindsay Jesteadt,4,5 Kristen McCausland,6 Jane Lazar Tucker,6 Gretchen Murphy,3 Anne Marie Morse,7 David T. Plante8

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 PRESENTATION
Vibrance-2: A Randomized Phase 2 Study Evaluating Efficacy and Safety of the Orexin 2 Receptor Agonist Alixorexton in Patients With Narcolepsy Type 2
AUTHOR(S)

Richard K. Bogan,1 Giuseppe Plazzi,2,3 Emmanuel Mignot,4 Rafael del Río Villegas,5,6 Bruce Corser,7 Brendon J. Yee,8 Diego García-Borreguero,9 Chad Ruoff,10 David T. Plante,11 Hailu Chen,12 Alexandra Lovett,12 Michael J. Doane,12 Craig Hopkinson,12 Bhaskar Rege,12 Julie Himes12

View presentation
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Polysomnographic Findings in Pediatric Patients With Narcolepsy Type 1 and Narcolepsy Type 2: A Retrospective Review
AUTHOR(S)

Sally Ibrahim, MD1,2; Kiran Maski, MD, MPH3; Anne Marie Morse, DO4; Rakesh Bhattacharjee, MD5; Judith Owens, MD3; Luis E. Ortiz, MD6; Gary Feldman, MD7; Narong Simakajornboon, MD8; Joshua Henderson, BA9; Jennifer Gudeman, PharmD10,a; Brian Abaluck, MD11; Femida H. Gwadry-Sridhar, RPh, PhD9 
 

View poster
Sleep-wake disorders